This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
F12 / Coagulation factor XII · Western blot design guide
Design a Western Blot for F12
Real validated F12 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-F12 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
F12 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | Cleaved fragment; mass unreported | |
| Gel | 12–15% (standard starting point) | |
| Negative control | Adipose tissue (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| Lead specificity | Cleaved target; verify fragment size for this antibody | |
| PTM | Glycosylated + Cleaved | |
| Caveat | Heavy glycosylation | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
Section 1
Real Curated F12 Western Blot Protocols
The A01226 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | various cells (catalog A01226) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A01226; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected F12 Western Blot Band Size?
The selected Anti-Cleaved-Factor XII HC (R372) F12 Antibody is labeled for cleaved factor XII heavy chain. The 67.8 kDa UniProt value is the predicted mass of the full-length precursor, not an expected mass for the cleaved heavy chain. Factor XII undergoes proteolytic processing into heavy- and light-chain products; the supplied caption gives no empirical fragment mass.
| Band above 67.8 kDa, possibly broad | Glycosylation can shift intact factor XII above its predicted precursor mass, but this antibody is labeled for cleaved heavy chain. Do not assign such a band to the target by size alone. |
| Smear around a band | Variable glycosylation may broaden migration of factor XII species that retain glycosylated regions. Confirm which species the antibody detects. |
| Band smaller than the precursor | A cleaved heavy-chain product may migrate below the full-length precursor. The caption supplies no empirical fragment mass, so size alone cannot identify it. |
| Little or no band in whole-cell lysate | Factor XII is secreted, and a cleavage-specific heavy-chain signal also depends on proteolytic processing. Assess a suitable secreted-protein sample and processing conditions. |
💡Expected F12 appearanceThe selected Anti-Cleaved-Factor XII HC (R372) F12 Antibody is labeled for a proteolytically cleaved heavy-chain product. UniProt's 67.8 kDa prediction describes the full-length precursor, not this fragment. Glycosylation may affect migration when sites are retained; the supplied caption reports no empirical fragment mass.
| 67.8 kDa predicted precursor mass | Reference for the unglycosylated full-length sequence; it does not set the cleaved heavy-chain band position. |
| O-linked fucose at Thr109 | Adds glycan mass to species retaining this region; its effect on an observed band depends on which fragment is detected. |
| N-linked glycosylation at Asn249 | Can affect migration and band breadth when the detected species retains this site. |
| O-linked glycosylation at Thr299, Thr305, Ser308, Thr328, Thr329, and Thr337 | May create glycoform heterogeneity in species retaining these sites; do not assume every site is present in the detected fragment. |
| Signal peptide at residues 1–19 | Its removal changes the secreted protein's backbone, but it does not explain the proteolytic heavy- and light-chain products targeted here. |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Factor XII is secreted; cleaved heavy-chain abundance also depends on processing. | Check a secreted-protein sample and whether cleavage occurred under the sample conditions. |
| Band higher than expected | Glycosylation can alter migration, while the 67.8 kDa prediction applies to the full-length precursor. | Compare with a deglycosylated aliquot and verify the detected species; do not use the precursor mass as a fragment target. |
| Band lower than expected | Proteolytic processing can yield a heavy-chain product smaller than intact factor XII. | Assess cleavage and band identity with an appropriate comparison; the supplied caption gives no fragment mass. |
| Broad smear instead of sharp band | Heterogeneous glycosylation may change apparent migration of a detected species. | Compare untreated and deglycosylated aliquots. |
| Multiple bands | Glycoforms and distinct proteolytic products may migrate separately. | Compare processing conditions and cellular versus secreted fractions; assess glycosylation and antibody specificity. |
| Weak or no signal | Secretion or limited formation of the cleaved heavy-chain target may reduce signal. | Concentrate a suitable secreted-protein sample and assess whether the target cleavage occurred. |
Experiment evidence
Western blot images showing F12 band
A01226 · F12
A01226 · F12
A01226-1 · F12
A01226-2 · F12
A01226-3 · F12
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for F12 Western blot
🧪For positive controls for F12 in Western blot, you can use an HPA-IHC candidate positive sample if identified; none is supplied here.
Positive control: No high/medium HPA tissue identified
Negative control: Adipose tissue (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: F12 is secreted, so whole-cell lysate may give little signal; a positive sample cannot be selected from the supplied HPA data.
HPA tissue expression evidence for F12
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced F12 Western Blot Tips
Deeper troubleshooting and optimisation questions for F12, answered from its protein features.
How should F12 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could F12 isoforms explain multiple bands?
Isoforms · Only one isoform is listed. Consider glycosylation and proteolytic processing into heavy- and light-chain products before assigning additional bands to isoforms; confirm which bands this cleavage-specific antibody detects.
Do annotated modifications prove a band shift?
PTM · The linked UniProt record describes protein features. A modification annotation alone does not demonstrate a visible shift; retain any condition or experimental qualifier attached to it.
Does this guide establish induction of F12?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
What transfer method to use for F12 Western blot?
Transfer · The supplied information does not specify a transfer method or an empirical mass for the cleaved heavy chain. Choose and verify transfer conditions for the range of species being assessed, rather than treating the 67.8 kDa precursor prediction as the fragment's expected size.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A01226 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should F12 be quantified?
Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.
Why might F12 migrate differently from its predicted 67.8 kDa?
Interpretation · The 67.8 kDa prediction describes the full-length unglycosylated precursor. Glycosylation and processing can change migration, and the selected Anti-Cleaved-Factor XII HC (R372) F12 Antibody is labeled for cleaved heavy chain. No observed fragment size was supplied.
Factor XII is a secreted zymogen that undergoes proteolytic processing into heavy- and light-chain products. Activation may change the cleaved heavy-chain signal, but the supplied caption gives no empirical fragment mass. The R372 site label is retained as stated and is not equated with a differently numbered site.
Factor XII is secreted, so consider a sample containing secreted protein. For this cleavage-specific heavy-chain antibody, also consider whether the sample contains processed factor XII; signal peptide removal alone does not establish that.
Assess glycosylation and proteolytic processing, including which products retain the antibody's target. One listed isoform does not support assigning extra bands to alternative isoforms. Band identity cannot be established from size alone.
Factor XII is a secreted zymogen that undergoes proteolytic processing into heavy- and light-chain products. Activation may change the cleaved heavy-chain signal, but the supplied caption gives no empirical fragment mass. The R372 site label is retained as stated and is not equated with a differently numbered site.
Factor XII is secreted, so consider a sample containing secreted protein. For this cleavage-specific heavy-chain antibody, also consider whether the sample contains processed factor XII; signal peptide removal alone does not establish that.
Assess glycosylation and proteolytic processing, including which products retain the antibody's target. One listed isoform does not support assigning extra bands to alternative isoforms. Band identity cannot be established from size alone.
Boster reagents
F12 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-Cleaved-Factor XII HC (R372) F12 Antibody
Cat # A01226
Real WB data
Anti-Coagulation factor XII F12 Antibody
Cat # A01226-1
Real WB data
Anti-F12 (HC) Antibody
Cat # A01226-2
Real WB data
Anti-Cleaved-Factor XII HC (I20) F12 Antibody
Cat # A01226-3
Four the supplier anti-F12 antibodies have WB images. Their descriptions cover F12, the heavy chain, and cleavage-specific forms. The supplied records give assay cues, but no publication evidence or cross-antibody comparison.
Which to pick: Choose A01226-1 for general F12 WB, A01226-2 for heavy-chain analysis, A01226 for cleaved heavy chain at R372, or A01226-3 for the Cleaved-Ile20 form. All four have WB images; confirm the target form and sample fit before use.
Source: BosterBio F12 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry P00748.
- Human Protein Atlas. F12 tissue expression.
- PMC11752705 — target-verified WB comparison
- PMC6311011 — target-verified WB comparison
- PMC6299215 — target-verified WB comparison